Background: cadmium is a widespread toxic metal with potential cardiovascular effects, but no studies have evaluated cadmium and incident cardiovascular disease. We evaluated the association of urine cadmium concentration with cardiovascular disease incidence and mortality in a large population-based cohort. Methods: We conducted a prospective cohort study of 3348 american indian adults 45-74 years of age from arizona, Oklahoma, and north and South Dakota, who participated in the Strong Heart Study in 1989-1991. Urine cadmium was measured using inductively coupled plasma mass spectrometry. Follow-up extended through 31 December 2008. Results: the geometric mean cadmium level in the study population was 0.94 μg/g (95% confidence interval [ci] = 0.92-0.96). We identified 1084 cardiovascular events, including 400 deaths. after adjustment for sociodemographic and cardiovascular risk factors, the hazard ratios (Hrs) (comparing the 80th to the 20th percentile of urine cadmium concentrations) was 1.43 for cardiovascular mortality (95% ci = 1.21-1.70) and 1.34 for coronary heart disease mortality (1.10-1.63). the corresponding Hrs for incident cardiovascular disease, coronary heart disease, stroke, and heart failure were 1.24 (1.11-1.38), 1.22 (1.08-1.38), 1.75 (1.17-2.59), and 1.39
C
admium is a toxic metal with widespread population exposure through smoking, diet, and ambient air. 1 in addition to being a carcinogen, cadmium has been associated with kidney disease, bone disease, and cardiovascular disease.
2 in cross-sectional epidemiologic studies, low-tomoderate cadmium exposure has been associated with hypertension, [3] [4] [5] chronic kidney disease, [6] [7] [8] diabetes, 9 carotid atherosclerosis, 10, 11 peripheral arterial disease, 12,13 myocardial infarction, 14, 15 and stroke and heart failure. 16 in prospective studies, cadmium was associated with increased cardiovascular mortality in the US general population. 17, 18 Mechanistic animal and experimental data support a role for cadmium in atherosclerosis, including increased endothelial permeability by inhibiting cell proliferation and promoting cell death. 10, 19 establishing cadmium as a cardiovascular risk factor, however, has been limited by the lack of data on its association with incident cardiovascular events and by the potential for confounding by smoking, a source of cadmium exposure.
We evaluated the prospective association of urine cadmium (an established biomarker of cumulative cadmium exposure) 1 with fatal and nonfatal cardiovascular disease incidence and all-cause mortality in the Strong Heart Study, a large population-based prospective cohort study of cardiovascular disease in american indian communities in arizona, Oklahoma, and north and South Dakota. 20 this study, conducted in a population with high rates of cardiovascular disease, is one of the major cardiovascular cohorts funded by the national Heart, lung, and Blood institute and has served as a model for evaluation of multiple physiologic and environmental risk factors. established risk factors for cardiovascular disease in this cohort include male sex, older age, increased low-density lipoprotein (lDl) cholesterol, decreased high-density lipoprotein (HDl) cholesterol, increased dietary fat intake, smoking, hypertension, decreased kidney function, and diabetes. [21] [22] [23] [24] [25] the cardiovascular role of environmental exposures, such as cadmium, has not been evaluated in this cohort.
METHODS

Study Population
From 1989 to 1991, men and women of age 45-75 years from 13 american indian communities in arizona, Oklahoma, and north and South Dakota were invited to participate in this cohort study. in arizona and Oklahoma, every eligible person was invited, whereas in north and South Dakota a cluster sampling technique was used. 20 the overall participation rate was 62%. 26 Participants (n = 4,549) were similar to nonparticipants in age, body mass index, and selfreported frequency of diabetes, but were more likely to be women and have hypertension.
We used data from 4218 participants who were free of self-reported cardiovascular disease at baseline. We further excluded 517 participants who were missing urine cadmium determinations because of insufficient urine left for metal analysis; 139 participants with missing smoking information; and 214 participants missing other variables of interest, leaving 3348 participants for this study. included participants were similar to those excluded because of missing data (data not shown). the study protocol was approved by the institutional and indian Health Service review Boards and the participating american indian communities. all the participants provided oral and written informed consent.
Baseline Data Collection
Sociodemographic data (age, sex, race/ethnicity, postmenopausal status, education), smoking history (smoking status and pack-years), alcohol drinking status, medical history, and medication use were obtained from the baseline questionnaire by trained and certified staff. 20 Body mass index was calculated as measured weight in kilograms divided by measured height in meters squared. three consecutive blood pressure determinations were taken, 20 and the last two determinations were averaged. Hypertension was defined as a mean systolic blood pressure ≥140 mmHg, a mean diastolic blood pressure ≥90 mmHg, or antihypertensive medication use.
total and HDl cholesterol were measured in fasting serum samples on the roche-Hitachi 717 platform (Boehringer-Mannheim/roche Diagnostics, indianapolis, in). lDl cholesterol was estimated by the Friedewald equation. 27 Hyperlipidemia was defined as an estimated lDl cholesterol ≥130 mg/dl. Plasma glucose was measured by the hexokinase method. Hba1c was measured by high-pressure liquid chromatography. 28 Diabetes was defined as a fasting glucose ≥126 mg/dl, a 2-hour postload glucose ≥200 mg/dl, an Hba1c ≥6.5%, or use of insulin or an oral hypoglycemic agent. Plasma creatinine was measured by an alkaline picrate rate method. estimated glomerular filtration rate was calculated from calibrated creatinine, age, and sex using the Modification of Diet in renal Disease Study formula without an ethnicity factor. 25 
Urine Cadmium Determinations
Spot (random) urine samples were collected in the morning of the baseline visit in polypropylene tubes, frozen within 1-2 hours, shipped buried in dry ice, and stored at −80°c in the Penn Medical laboratory, MedStar Health research institute (Hyattsville, MD, and Washington, Dc). in 2009, up to 1.0 ml of urine from each participant was transported on dry ice to the institute of chemistry-analytical chemistry, Karl Franzens University (graz, austria) and stored at −80°c until analyses.
in graz, the sample was thawed and a portion of the supernatant was diluted 10-fold with 10% v/v nitric acid (containing the internal standards ge, in, lu at a concentration of 44 µg/l) and centrifuged for 10 minutes at 1.3 × 10 4 g. the cadmium concentration in this solution was determined using inductively coupled plasma mass spectrometry (agilent 7700x icPMS; agilent technologies, Waldbronn, germany). the "Seronorm™ trace elements urine blank" (SerO aS, Billingstad, norway), with a labeled cadmium concentration of 0.35 µg/l, was used for quality control. We obtained a cadmium mean value of 0.38 (SD = 0.07) µg/l (n = 66). in addition, the cadmium concentration in the certified reference Material niSt 1643e "trace elements in water" (niSt, gaithersburg, MD), with a mean certified concentration of 6.57 µg/l (SD = 0.07), was determined with each run. We obtained a mean value of 6.42 µg/l (SD = 0.38) (n = 79).
the limit of detection for urine cadmium was 0.015 µg/l. in one participant below the limit of detection, the cadmium concentration was imputed as the limit of detection divided by the square root of two. Urine cadmium concentrations were corrected for molybdenum oxide interference using the formula [cd]corr = [cd] − 0.0016 × [Mo]. 29 to account for urine dilution, urine cadmium concentrations were expressed in micrograms per gram of urine creatinine. Urine creatinine was measured at the laboratory of the national institute of Diabetes and Digestive and Kidney Disease, epidemiology and clinical research Branch (Phoenix, aZ) by an alkaline picrate rate method. 20 cardiovascular incidence, including both fatal and nonfatal events, was the primary outcome of this study. incident cardiovascular endpoints during follow-up were assessed by annual mortality and morbidity surveillance reviews of hospitalization and death records and at two research clinic visits conducted in 1993-1995 and 1998-1999. Follow-up was 99.8% complete for mortality and 99.2% complete for morbid events. 26 When possible cardiovascular events were identified, medical records were reviewed by mortality and morbidity review committees composed of physician reviewers who assigned cardiovascular events. Detailed definitions of fatal and nonfatal events have been described. 20,30 incident coronary heart disease was defined as the first occurrence of definite fatal myocardial infarction, sudden death because of coronary heart disease, nonfatal myocardial infarction, or definite nonfatal coronary heart disease. incident cases of stroke were defined as the first occurrence of definite or possible fatal or definite nonfatal stroke. incident cases of heart failure were defined as the first occurrence of definite or possible fatal or definite nonfatal heart failure. the composite endpoint of all cardiovascular disease was defined as the occurrence of a cardiovascular death or definite nonfatal coronary heart disease, stroke, or heart failure. all-cause mortality included all causes of death and was a secondary outcome in the study.
time to event was calculated as the difference between age at the date of the baseline examination and the age at the date of the cardiovascular event, age at the date of death, age 90 years, or age at 31 December 2008, whichever occurred first. the mean follow-up time among participants who did not develop a cardiovascular event over follow-up was 15 years.
Statistical Methods
creatinine-corrected urine cadmium levels were markedly right-skewed, and we log-transformed them for statistical analyses. the prospective association of urine cadmium concentrations with cardiovascular disease incidence was evaluated using cox proportional hazards models with age as time scale and individual starting follow-up times (age at baseline examination) treated as staggered entries. creatinine-corrected urine cadmium concentrations were introduced in the models as cadmium quartiles or as log-transformed cadmium concentrations to compare 80th versus 20th percentile (interquintile range). the nonparametric underlying baseline hazards were allowed to differ by study region (arizona, Oklahoma, and north and South Dakota), using the function strata() in the cox regression model. the assumption of hazards proportionality was visually assessed based on the smoothed association between age and scaled Schoenfeld residuals, 31 with no major departures from proportionality.
We used three statistical models with progressive adjustment for the following variables at baseline. Model 1 adjusted for sex. Model 2 additionally adjusted for postmenopausal status for women (no, yes), education (<12, ≥12 years of education completed), body mass index (continuous), diabetes (no, yes), total cholesterol (continuous), estimated lDl cholesterol (continuous), hypertension (no, yes), and estimated glomerular filtration rate (continuous). Model 3 additionally adjusted for smoking status (never, former, current) and cumulative smoking dose (pack-years modeled as restricted cubic splines with knots at 10, 20, and 30 pack-years). adjustment for age was not needed because the time scale in our cox model was age (ie, intrinsically conditioning on age). alternative cox model specification using time since examination as time scale with adjustment for age resulted in similar results. P values for linear trend were obtained from Wald tests for log-transformed urine cadmium in regression models. We modeled nonlinear relationships between cadmium levels and incident cardiovascular endpoints by using restricted quadratic splines with knots at the 10th, 50th, and 90th percentiles of the creatinine-corrected urine cadmium distribution (0.40, 0.92, and 2.14 μg/g, respectively). exploratory subgroup analyses were conducted by including interaction terms for log-transformed urine cadmium concentrations with indicator variables for subgroups defined by age (<65, ≥65 years), sex (men, women), education (<12, ≥12 years of education completed), body mass index (<30, ≥30 kg/m 2 ), smoking status (never, former, current), hypertension (no, yes), diabetes (no, yes), reduced estimated glomerular filtration rate (<60, ≥60 ml/min/1.72 m 2 ), and hyperlipidemia (lDl-cholesterol <130, ≥130 mg/dl) in separate models. P values for interaction were obtained by using Wald tests for multiple coefficients. We conducted sensitivity analysis by modeling urine cadmium concentrations in micrograms per liter and adjusting for urine creatinine concentrations instead of dividing urine cadmium by urine creatinine concentrations, with consistent findings (data not shown). Because cadmium is a well-known nephrotoxicant, and kidney disease could potentially mediate part of the cardiovascular effects induced by cadmium, adjustment for estimated glomerular filtration rate in our final model could have resulted in an attenuation of the association. We conducted a sensitivity analysis removing estimated glomerular filtration rate from the final model with no changes to the association (data not shown). Finally, to eliminate the possibility of a birth cohort effect, we ran additional models allowing the nonparametric underlying baseline hazards to differ by the interaction of study region and age groups (<54, 54-64, and ≥64 years), with consistent findings. all statistical analysis were conducted using r-software.
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RESULTS
the overall median of urine cadmium concentrations at baseline was 0.92 (interquartile range = 0.61-1.45), and the geometric mean was 0.94 μg/g creatinine. increasing urine cadmium concentrations were associated with less education, higher age, body mass index, and cigarette pack-years; increasing prevalence of ever-smoking status; and decreasing prevalence of current drinking status, diabetes, and hypertension (table 1) .
During follow-up, a total of 1084 participants developed cardiovascular disease, 766 coronary heart disease, 244 with stroke, and 328 with heart failure. the numbers of all-cause, cardiovascular disease, and coronary heart disease deaths were 1382, 400, and 307, respectively. creatinine-corrected urine cadmium concentrations were associated with mortality endpoints in all three models (table 2). Fully adjusted hazard ratios (Hrs) comparing the highest to the lowest quartile of urine cadmium concentrations for all-cause, cardiovascular, and coronary heart disease mortality were 1. in dose-response analyses, the association between cadmium concentrations and cardiovascular endpoints showed positive dose-response relationships (tables 2 and 3, and Figure 1) , with no statistically significant departures from linearity except for incident stroke and heart failure (P value for nonlinear terms = 0.001 and 0.02, respectively).
the associations between cadmium and cause-specific cardiovascular endpoints were similar in most subgroups including never-smokers (Figure 2 and eFigure 1 and eFigure 2, eappendix, http://links.lww.com/eDe/a662), except for the association between cadmium and incident stroke by smoking status (eFigure 2, http://links.lww.com/eDe/a662). Participants with diabetes and without chronic kidney disease showed stronger associations with most cardiovascular endpoints.
DISCUSSION
cadmium exposure, measured by urine cadmium concentrations, was associated with increased risk of all-cause and cardiovascular mortality and with increased incidence of cardiovascular events in middle-aged to elderly men and women followed for up to 19 years. the associations persisted after adjusting for traditional cardiovascular risk factors and were similar in most subgroups evaluated, including neversmokers. Our findings, together with evidence on the association between cadmium and cardiovascular mortality 17, 18, 33, 34 and risk factors, [3] [4] [5] [6] [7] [8] [9] [10] [11] and with mechanistic evidence, 10, 19 support the role of cadmium as a cardiovascular risk factor. cadmium was used extensively in consumer products (eg, pigments, batteries, coatings, and plastic stabilizers) throughout the 20th century.
1 currently, cadmium is still used in batteries and solar panels. Moreover, cadmium remains an important soil contaminant from industrial releases and the use of cadmium-containing phosphate fertilizers. 1, 35 exposure to cadmium in the population occurs through tobacco smoke, certain foods (shellfish, offal, and some vegetables and grains that concentrate cadmium from soil), and ambient air, particularly in the vicinity of industrial and hazardous waste sites and in occupational settings. 1, 36, 37 no information is available on specific sources of cadmium exposure in american indian populations, but urine cadmium concentrations in the Strong Heart Study participants were higher than in the general US population for the same age group and time period. 38 although the prevalence of smoking is higher in some american indian communities compared with other US ethnic groups, 39, 40 their intensity of smoking is markedly lower, 40 suggesting that sources of exposure other than smoking may be responsible for the increased urine cadmium concentrations. Studies of b Models comparing the 80th (1.62 μg/g) to the 20th (0.55 μg/g) percentiles of urine cadmium distributions and associated test for trend were obtained from cox proportional hazards models with log-transformed cadmium as a continuous variable, except for stroke and heart failure where cadmium was introduced as restricted quadratic splines with knots at percentiles 10th, 50th, and 90th because of the nonlinear relationships. other native american populations from the United States, canada, and Mexico have suggested that sources of cadmium include nearby contaminating factories and mining 41, 42 and surface dust in jewelry-making homes. 43 another activity that could be relevant for cadmium exposure in our population is small-scale motor vehicle repair. 37 Several studies have found no association between occupational cadmium exposure and cardiovascular disease. [44] [45] [46] Occupational studies, however, have been limited in the quantification of cadmium exposure, assessment of cardiovascular outcomes, and measurement of relevant confounders. Workers could also be affected by the healthyworker effect. Of the few studies that have evaluated the prospective association between cadmium exposure and cardiovascular mortality, most have found positive associations. 17, 18, 33, 34 in the Japanese Kakeshi river basin, markedly high urine cadmium concentrations were associated with heart failure mortality but not with cerebrovascular mortality. 33 in that study, however, the number of deaths was small, and the associations were not adjusted for smoking. in the general US population, urine cadmium concentrations were positively associated with cardiovascular mortality in men who participated in the third national Health and nutrition examination Survey (nHaneS iii, 1988-1994) 17 and (consistent with our findings) in both men and women who participated in nHaneS 1999-2004. 18 in nHaneS 1999-2004, the Hr for cardiovascular mortality, comparing the 80th (0.57 μg/g creatinine) versus 20th (0.14 μg/g creatinine) percentile of urine cadmium concentrations, was 1.74 (95% ci = 1.07-2.83). 18 in a Belgian population, urine cadmium concentrations at baseline were associated with all-cause mortality (Hr = 51, 52 and kidney disease. 53 cadmium-related vascular damage could be partly promoted by dysfunctional metallothionein production in endothelial cells. 54 in addition, cadmium could induce cardiovascular disease through epigenetic and endocrine disruption mechanisms, involving aberrant Dna methylation, histone modifications and changes in microrna expression, 55 and activation of the estrogen receptor. [56] [57] [58] the associations between cadmium and cardiovascular endpoints observed in the Strong Heart Study are also consistent with reported cross-sectional associations of cadmium exposure with peripheral arterial disease, 12,13 myocardial infarction diagnosed by the cardiac infarction injury Score (an electrocardiographic classification system to assess the extent of cardiac injury in postmyocardial infarction 59 ), 14 carotid atherosclerosis, 10, 11 and self-reported coronary heart disease, stroke, and heart failure 15,16 -further supporting a role for cadmium in cardiovascular disease development.
Smoking is an important determinant of cadmium exposure 1 and a major cardiovascular risk factor. 60 it has been suggested that cadmium could be a mediator of tobacco-related cardiovascular disease. 12, 61 Our findings support the hypothesis that cadmium is an independent cardiovascular risk factor, as the association remained after we adjusted for smoking status and cumulative smoking dose. residual confounding FIGURE 1. Hazard ratios for cardiovascular mortality and incidence by urine cadmium concentrations (n = 3,348). Lines represent adjusted hazard ratios based on restricted quadratic splines for log-transformed cadmium concentrations with knots at the 10th, 50th, and 90th percentiles, which correspond to 0.40, 0.92, and 2.14 μg/g creatinine, respectively. The reference was set at the 10th percentile of cadmium distribution. Vertical bars represent the histogram of urine cadmium distribution in the study population. The models were adjusted for sex, postmenopausal status for women (yes, no), education (<high school, ≥high school), body mass index (kg/m 2 ), total cholesterol (mg/dl), estimated LDL cholesterol (mg/dl), hypertension (yes, no), diabetes (yes, no), estimated glomerular filtration rate (ml/min/1.73 m by smoking is possible, however, because smoking status and pack-years were defined by self-report and we do not have information on secondhand smoke exposure. nevertheless, the association between urine cadmium and cardiovascular mortality remained in previous studies 17, 18 after adjustment for serum cotinine, an objective biomarker of cigarette smoking. Moreover, the similar association between cadmium exposure and cardiovascular endpoints in never-smokers compared with ever-smokers makes residual confounding less likely.
Strengths of this study include the prospective design and the long follow-up; the low rate of losses to follow-up; the high number of events; the low limit of detection for urine cadmium; and the standardization and quality control of data collection, laboratory analyses, and identification of incident cardiovascular events. 20 these data from american indians provide information for an understudied ethnic group.
Our study has several limitations. First, we used a single baseline urine cadmium determination as a biomarker of exposure. although urine cadmium has a half-life of decades, 1 regression dilution bias because of nondifferential measurement error may have resulted in an underestimation of the associations. Second, american indian communities have a higher burden of cardiovascular disease and its risk factors, as well as higher mortality because of noncardiovascular causes, compared with some other populations. 62 it is uncertain whether our results can be completely generalized to populations with a different cardiovascular risk factor profile, although cadmium toxicity pathways are likely to be common to many populations. Our population, for instance, is characterized by a high burden of diabetes. in our exploratory subgroup analysis, we found that the association was stronger among participants with diabetes, although those findings were not statistically significant and must be taken with caution. Finally, there is a concern that end-stage renal disease associated with diabetic nephropathy and consequent renal replacement therapies could change chronic cadmium accumulation in the body. in our study, we had only two participants at baseline with kidney transplantation and 14 participants with end-stage renal disease (defined as a glomerular filtration rate <15 ml/min/1.73 m 2 )-none of them under dialysis. the exclusion of those participants did not change the observed associations (data not shown).
in conclusion, cadmium exposure was prospectively associated with increased cardiovascular disease and mortality in both men and women. the findings of this study together with accumulated evidence on cadmium cardiovascular toxicity and previous epidemiologic findings can contribute to evaluate causality of the association between cadmium and cardiovascular disease based on established criteria, 63 including consistency, temporality, dose-response relationship, and biological plausibility. cardiovascular diseases, including coronary heart disease, heart failure, and stroke, are major causes of death, long-term functional disability, and medical costs around the world. 64, 65 if cadmium is confirmed as a µ µ µ µ FIGURE 2. Hazard ratios for cardiovascular disease mortality and incidence by urine cadmium concentrations in smoking status subgroups (never-smokers, n = 1,145; eversmokers, n = 2,203). Methodological details are the same as for Figure 1 .
